It is affiliated with NewYork-Presbyterian Hospital, Weill Cornell Medical College and is a leader in research programs for cancer and diabetes.
In 1962, the unit became known as the Renal Laboratory and moved to the New York Hospital-Cornell Medical Center where it expanded to the Rogosin Renal Laboratories, named in honor of Israel Rogosin (1886-1971), an American textile industrialist and philanthropist who supported the foundation of the New York Hospital-Cornell Medical Center, by giving a total of 4 million dollars in 1962 and 1965.
With expansion into research and treatment of cardiovascular disease and cancer, The Rogosin Institute became an independent corporate entity in 1983.
The institute pioneered clinical research of LDL apheresis[3] in the early 1980s, which led to the adoption of the procedure to treat patients with the genetic form of extremely high cholesterol.
Scientists at the Rogosin Institute have developed non-invasive procedures, less expensive and less painful than renal biopsies, for diagnosing rejection of transplanted kidneys.